Study Evaluating Zr-Panitumumab for Assessment of Suspected Metastatic Lesions on 18F-FDG-PET/CT in Head and Neck Squamous Cell Carcinoma

Inclusion Criteria:

   - Age ≥ 19 years.

   - Biopsy confirmed diagnosis of squamous cell carcinoma of the head and neck.

   - Subjects diagnosed with any T stage, any subsite within the head and neck. Subjects
   with recurrent disease or a new primary will be allowed.

   - Must have standard of care 18F-FDG-PET/CT scan ≤ 30 days of Day 0 with suspected
   metastatic lesions.

   - Have acceptable hematological status, coagulation status, kidney function, and liver
   function including the following clinical results:

      - Hemoglobin ≥ 9gm/dL

      - White blood cell count > 3000/mm3

      - Platelet count ≥ 100,000/mm3

      - Serum creatinine ≤ 1.5 times upper reference range

      - PTT = 11.5 - 14.4 seconds

      - INR = 0.9 - 1.2

Exclusion Criteria:

   - Myocardial infarction (MI); cerebrovascular accident (CVA); uncontrolled congestive
   heart failure (CHF); significant liver disease; or unstable angina within 6 months
   prior to enrollment

   - History of infusion reactions to other monoclonal antibody therapies

   - Pregnant or breastfeeding

   - Magnesium or potassium lower than the normal institutional values

   - Subjects receiving Class IA (quinidine, procainamide) or Class III (dofetilide,
   amiodarone, sotalol) antiarrhythmic agents

   - Subjects with a history or evidence of interstitial pneumonitis or pulmonary fibrosis

   - Severe renal disease or anuria

   - Known hypersensitivity to deferoxamine or any of its components